Skip to content
naulon
Get started

No retraction, correction or concern found when last checked on Oct 22, 2026.

The rising crisis of illicit fentanyl use, overdose, and potential therapeutic strategies

Ying Han, Wei Yan, Yongbo Zheng and 3 more

Translational Psychiatry · 2019 · Review · CC BY

doi:10.1038/s41398-019-0625-0

Abstract

Fentanyl is a powerful opioid anesthetic and analgesic, the use of which has caused an increasing public health threat in the United States and elsewhere. Fentanyl was initially approved and used for the treatment of moderate to severe pain, especially cancer pain. However, recent years have seen a growing concern that fentanyl and its analogs are widely synthesized in laboratories and adulterated with illicit supplies of heroin, cocaine, methamphetamine, and counterfeit pills, contributing to the exponential growth in the number of drug-related overdose deaths. This review summarizes the recent epidemic and evolution of illicit fentanyl use, its pharmacological mechanisms and side effects, and the potential clinical management and prevention of fentanyl-related overdoses. Because social, economic, and health problems that are related to the use of fentanyl and its analogs are growing, there is an urgent need to implement large-scale safe and effective harm reduction strategies to prevent fentanyl-related overdoses.

Full text

From PubMed Central, U.S. National Library of Medicine, as current on Oct 22, 2026. Paragraph numbers are ours, so an answer can point at one.

Introduction

Fentanyl was first developed in 1960 by Paul Janssen as a potent opioid anesthetic and analgesic. At the time, fentanyl was the fastest-acting opioid discovered to date and more powerful than morphine (50–100 times) and heroin (30–50 times),. Transdermal, intravenous, and transbuccal fentanyl administration and several other drugs with chemical structures that are similar to fentanyl have been developed, approved, and used for surgical anesthesia and the management of severe cancer pain and perioperative pain, eventually becoming the most often used synthetic opioid in clinical practice–. Since 1979, fentanyl and its analogs have been synthesized in laboratories and sold as heroin substitutes or mixed with other illicitly sourced drugs, leading to an increase in fentanyl-related overdose deaths,. Postmortem studies have consistently found pulmonary edema, congestion, and needle puncture sites in these victims. Based on data from the National Vital Statistics System, 599,255 drug overdose deaths occurred from 1979 to 2016 in the United States, and the overall mortality rate has seen exponential growth. Fentanyl-related overdose deaths predominantly occurred in the northeastern United States, mostly affecting younger people (20–40 years of age), and grew sharply since 2013.

Rapid death from ingesting fentanyl has become increasingly more common. Its high potency, fast onset of action, and duration of the desired effect may be particularly important contributing factors to the higher risk of overdose deaths and social consequences. Fentanyl has become a major contributor to cocaine-related fatal overdoses. The rate of fentanyl-related overdose deaths increased 55% between 2015 and 2017 in New York city,. Synthetic opioids are also increasingly detected in illicit supplies of heroin, methamphetamine, and counterfeit pills. Analysis of a sampling of 1 million unique patients’ urine drug test (UDT) specimens showed that positivity rates for fentanyl have increased by 1850% among cocaine positive UDT results and increased by 798% among methamphetamine-positive UDT results between January 2013 and September 2018. This mixture may lead to the increases in cocaine-related and methamphetamine-related overdoses. Moreover, the number of fatal overdoses from synthetic opioids, primarily fentanyl and its analogs, was 19,547 in 2016 in the United States, and this rate increased by 88% per year from 2013 to 2016–. The incidence of heroin-related overdose deaths stabilized in 2017, whereas deaths that involved other synthetic opioids continued to increase. Given the substantial individual and public health threats of this emerging problem, the present review summarizes the epidemic and evolution of illicit fentanyl use, its pharmacological mechanism of action, its adverse consequences, and the clinical management and prevention of fentanyl-related overdoses.

Epidemic and evolution of illicit fentanyl use

Fentanyl is currently approved and commonly used to treat breakthrough pain in cancer patients and various other clinical conditions that involve noncancer pain, such as postoperative pain. However, its potential for abuse and the rise in overdose deaths pose a serious challenge to public health–. Deaths that were attributable to illicit fentanyl use were first reported in the early 1980s and occurred sporadically in the United States,,. A surge in the occurrence of fentanyl-related fatalities among illicit drug users occurred in 2006. A total of 1013 deaths in six states occurred from April 4, 2005, to March 28, 2007. Since then, the prevalence of opioid-related mortality has increased persistently, and the number of reported fentanyl-related deaths more than doubled (from 2628 to 5544) between 2012 and 2014,,. The rate of fentanyl-related overdose deaths increased from <15% in 2010 to ~50% in 2017 in Marion County, Indiana. Overall overdose deaths and first-responder calls increased in a community-based sample in an impoverished neighborhood in Vancouver, Canada, in 2017, and fentanyl was detected in 52% of the subjects who were prescribed opioid agonist therapy. At the same time, fentanyl-related deaths also increased in Australia,.

The presence of fentanyl and its analogs has become a central contributor to the increase in the number of opioid-related overdose deaths. Preliminary estimates of opioid overdose deaths in the United States in 2016 revealed that fentanyl and its analogs (e.g., acetylfentanyl, furanylfentanyl, and carfentanil) have contributed to nearly half of opioid overdose deaths,,. Moreover, the number of deaths that were attributable to illicitly manufactured fentanyl and its analogs nearly quadrupled between July 2015 and June 2017 in Montgomery County, Ohio. Heroin-positive cases declined while methamphetamine-positive cases increased in these victims. Urine drug screens showed that the prevalence of recent fentanyl use in patients who received opioid agonist treatment in England was 3%, and multiple fatalities with synthetic fentanyl analogs were reported in northern England in early 2017,.

Fentanyl is ~30–50 times more potent than heroin, and smaller volumes of heroin and other drugs that are adulterated with fentanyl can produce powerful effects with lower production costs. Detecting fentanyl and its analogs in used syringes can reveal exposure risk. The fentanyl detection rate was significantly higher among drug users who injected drugs in the past 6 months compared with non-injection drug users. The prevalence of non-fatal overdose is very high among people who inject drugs–. The prevalence of intravenous fentanyl use among people who inject drugs in Australia is 8%. Given the narrow range between effective and lethal doses, this population is at high risk of overdose,,. The opioid crisis is likely attributable to illicitly manufactured fentanyl and its analogs around the world, especially when they are mixed with heroin and other drugs, and the route of administration,.

Many people who have survived fentanyl overdose appear to be unaware that they ever took the drug. Surveys from 17 harm reduction sites in British Columbia, Canada, revealed that the prevalence of fentanyl use was 29% (70/242; based on urine drug screen), 73% of whom report that they did not knowingly use fentanyl. Urine drug screens in methadone-maintained patients in Wayne County, Michigan, showed that 38% of 368 unique patients tested positive for fentanyl, and 67.3% of 113 patients reported that they did not know anyone who sought to obtain fentanyl in a subsequent anonymous survey. A high risk of overdose and deaths was found among this vulnerable population that exhibited high fentanyl exposure, thus highlighting the pressing need to develop appropriate harm-reduction strategies, such as surveillance, the development of early-warning systems, pill-testing technology about the presence of fentanyl in various drug products, naloxone training and distribution, overdose education, and urine screens,,. The vast majority of people reported their willingness to use rapid test strips to detect the presence of fentanyl in drugs or urine at home or utilize drug-checking services at supervised injection clinics,. Multiplex ultrahigh-performance liquid chromatography (UHPLC–MS)/liquid chromatography tandem mass spectrometry (LC–MS–MS)/liquid chromatography–quadrupole time-of-flight–mass spectrometry (LC–QTOF–MS) analyses have also been developed and validated for the detection of fentanyl and its analogs and metabolites in blood, hair, and oral fluid, which will be helpful for informing harm reduction behaviors and combating the fentanyl crisis–. A newly developed lateral flow immunoassay was also evaluated for effectiveness in the detection of fentanyl analogs.

Pharmacological mechanisms and side effects of fentanyl

Despite the beneficial clinical anesthetic and pain-relieving effects of fentanyl, the frequent use of fentanyl primarily affects the central nervous system (CNS) and gastrointestinal, cardiovascular, and pulmonary systems and can cause several side effects. Digestive symptoms, such as nausea, vomiting, and constipation, are common in patients who repeatedly use fentanyl,. Immunosuppression was also shown to be precipitated by analgesic opioid drugs, including fentanyl, in preclinical and clinical studies. Such immunosuppression can be especially dangerous in the elderly and already immunocompromised patients–. Additionally, fentanyl and synthetic opioids have other frequently reported side effects, including migraine, dizziness, vertigo, confusion, hallucinations, and a higher risk of fractures in the elderly–. Fentanyl has rewarding effects and thus high abuse potential. Its repeated use leads to the development of tolerance and drug dependence,. Analyses of adverse-event reporting systems in the United States, Europe, and the United Kingdom have shown that cases of fentanyl-related misuse, abuse, dependence, and withdrawal steadily increased between 2004 and 2018, resulting in prolonged hospitalization or death. Other mental disorders, such as depression, insomnia, and suicidality, can also occur with fentanyl abuse, contributing to relapse and a higher risk of respiratory depression or overdose death,. The treatment of these mental disorders may help prevent fentanyl-related fatalities and achieve abstinence.

Fentanyl is a full μ-opioid receptor agonist, but it also acts on δ- and κ-opioid receptors,. Fentanyl has been shown to exert its analgesic and lethal effects through different receptor populations in the CNS. It is eliminated from cerebrospinal fluid at approximately the same rate as morphine,. Acute naloxone administration antagonizes fentanyl-induced analgesia more than fentanyl-induced lethality. β-funaltrexamine was shown to inhibit both fentanyl-induced analgesia and lethality. Overdose-related concentrations of fentanyl were shown to block human ether-a-go-go-related gene (hERG) potassium channels in ventricular myocytes that were isolated from neonatal rats, which may contribute to fentanyl-related overdose death or sudden death.

Respiratory depression is the most dangerous adverse reaction to fentanyl that can result in lethality. In rats, intravenous injections of fentanyl dose-dependently decreased oxygen levels in the nucleus accumbens, basolateral amygdala, and subcutaneous space, followed by a delayed increase in glucose and fluctuations in brain temperature and metabolic brain activity–. Neuronal hypermetabolism that is induced by fentanyl and its analogs may damage the hippocampus and limbic system, causing an amnestic syndrome in patients who use fentanyl–. With regard to brain hypoxia and hypothermia, fentanyl has synergistic effects with heroin, which is consistent with the higher risk of overdose death that is associated with heroin–fentanyl mixtures,. Fentanyl-related respiratory depression is also dose-dependent, which reaches a peak 5 min after administration and requires 4 h to recover in humans. Such effects can lead to prolonged apnea and sudden death,,. Epidural fentanyl infusion has been shown to cause postoperative adult respiratory distress syndrome. The μ1-opioid receptor is involved in respiratory depression that is induced by fentanyl and its analogs but not morphine. Selective α4β2 nicotinic receptor agonist A85380 reversed fentanyl-induced respiratory depression in rats without significant side effects. The calcium-activated potassium channel blocker GAL021 was shown to attenuate morphine-induced respiratory depression in rats, mice, and nonhuman primates, and it produced stimulatory effects during alfentanil-induced respiratory depression, without affecting sedation in humans–. However, more studies are needed to confirm the efficacy and potential toxicity of A85380 and GAL021.

Many studies have reported cardiovascular symptoms after fentanyl-induced analgesia, such as myocardial ischemia, QTc interval prolongation, and bradycardia–. Fentanyl is commonly used during percutaneous coronary interventions, but the relative safety of its use requires further investigation because intravenous fentanyl has been reported to induce hypothermia, impair ticagrelor absorption, and cause antiplatelet effects–. Autopsy and toxicological analyses indicated that chronic fentanyl use may be responsible for hypertrophy, cardiac fibrosis, and atherosclerosis,,. Neither sigma nor opioid receptors are essential for the fentanyl-induced attenuation of muscarinic coronary contraction.

Fentanyl administration provides effective pain relief, but its long-term use can result in a lowering of pain thresholds,. This phenomenon of fentanyl-induced hyperalgesia is a challenge in the clinical management of perioperative and chronic pain. Recent studies showed that fentanyl-induced hyperalgesia was modulated by the activation of extracellular signal-regulated kinase in the laterocapsular division of the central nucleus of the amygdala (CeLC) and CaMKIIα in the CeLC–periaqueductal gray–rostral ventromedial medulla–spinal cord descending facilitative pain pathway in rats,.

Interventions for the management and prevention of fentanyl overdose

Similar treatments are prescribed for opioid use disorder and opioid overdose, including the Food and Drug Administration (FDA)-approved medications methadone, buprenorphine, extended-release naltrexone, and naloxone. Lofexidine, a central α2-adrenergic receptor agonist, was the first non-opioid medication that was approved by the United States FDA for the treatment of opioid withdrawal,. Lofexidine has fewer prescriptive barriers and comparable efficacy and safety relative to other opioid receptor agonizts, but it is generally more expensive. Sparse data are available on the effectiveness of interventions to prevent overdoses that are caused by illicitly manufactured fentanyl (Table 1). Compared with other opioid-related overdoses, illicit fentanyl-related overdoses appear to be accompanied by distinct symptoms, such as body and chest rigidity, dyskinesia, and slow or irregular heart rate, which can affect overdose management, such as oxygen provisions and appropriate doses of naloxone,. To avoid or reduce the adverse effects of fentanyl, the FDA proposed to control the duration of use and doses of fentanyl. One study showed that the majority of patients who were presumed to experience fentanyl overdose could be discharged after brief emergency room observation, thus unlikely requiring additional naloxone dosing in the emergency room.

There are limited data on the efficacy of methadone or buprenorphine for the treatment of illicit fentanyl use. A retrospective study in Rhode Island showed that 6 months of methadone maintenance protected against death and promoted abstinence in fentanyl-exposed patients, but relapse rates were still high. Buprenorphine is a μ-opioid receptor partial agonist and κ-opioid receptor antagonist that is commonly used to treat opioid use disorder. It also exerts antidepressant and anxiolytic activity and is a promising treatment for neonatal opioid withdrawal syndrome. A retrospective cohort study showed that 6-month treatment retention rates and opioid abstinence rates were not different between individuals who were positive for fentanyl or heroin at baseline before initiating buprenorphine treatment, indicating that buprenorphine may still be beneficial for treating fentanyl exposure. Repeated treatment with buprenorphine produced a greater magnitude of antinociceptive tolerance than higher-efficacy agonizts (e.g., morphine and etonitazene) in rats. Studies in pigeons and rhesus monkeys showed that the amount of tolerance that develops to the reinforcing potency of opioids depends on their efficacy, and the higher-efficacy μ-opioid receptor agonist sufentanil was more difficult to antagonize than the low-efficacy μ-opioid receptor agonist morphine–. These data indicate that buprenorphine may have lower efficacy for the treatment of fentanyl overdose compared with heroin overdose, although no human trials have been performed to date.

Naloxone is a μ-opioid receptor antagonist that is used to treat fentanyl-related overdose, regardless of the suspected route of administration. However, its efficacy is inconsistent, and safe dosing needs to be considered from the perspective of precipitating opioid withdrawal–. Recent studies also showed that extended-release naltrexone was equally safe and effective as a buprenorphine–naloxone combination at promoting abstinence and treatment retention once treatment was initiated, but fewer participants successfully initiated naltrexone treatment,. Larger or repeated doses of naloxone are speculated to be required for the treatment of fentanyl overdose because of its higher affinity for μ-opioid receptors. However, a study of a community naloxone distribution program in Allegheny County showed that the average doses of naloxone that were administered to reverse overdose did not change between 2013 and 2016, although the incidence of overdoses that were related to fentanyl and its analogs increased during the same time. A retrospective study of the fentanyl epidemic in Chicago showed that doses of naloxone up to 12 mg may effectively treat fentanyl overdose. Naloxone was shown to reverse transdermal fentanyl overdose-induced sedation, the reduction of body temperature, and the reduction of heart rate in dogs. A systematic review found a low incidence of mortality or serious adverse events that were caused by prehospital naloxone administration in opioid overdose patients, although the source of overdose was mostly heroin and not fentanyl. Additionally, seeking emergency medical help was positively associated with overdose victims who received higher doses of naloxone and rescue breathing in British Columbia, Canada. A survey of 316 street-recruited people who used opioids in Baltimore showed that the majority of them perceived the high risk of fentanyl-adulterated heroin and overdose, but most of them did not often carry naloxone with them. The early adoption and distribution of take-home naloxone have been reported to effectively prevent opioid overdose deaths–. Therefore, harm reduction strategies, such as safe injection sites, the expansion of available opioid agonist treatment, and overdose prevention training (e.g., carrying naloxone and not use drugs alone, higher dose or multiple administrations of naloxone), are needed to control the adverse effects of fentanyl and reduce overdoses.

Additionally, more potent, longer-acting opioid receptor antagonists are needed to prevent fentanyl-related overdose deaths. Compared with naloxone, nalmefene has been shown to have superior efficacy in reversing the carfentanil-induced loss of righting reflex and respiratory depression in rats. Nalmefene is generally well tolerated and is a recent option for patients with alcohol dependence–. Additionally, novel, selective, and potent μ-opioid receptor antagonists, such as 17-cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6α-(isoquinoline-3-carboxamido)morphinan (NAQ) and 17-cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6α-(indole-7-carboxamido)morphinan (NAN), have been reported to produce less opioid tolerance, dependence, and withdrawal signs. Furthermore, NAN pretreatment was shown to block the discriminative stimulus effects of fentanyl in rats. The orexin-1 receptor antagonist SB-334867 was also shown to decrease motivation and demand for fentanyl in rats. Therefore, these drugs could be considered candidates for the treatment of opioid use disorder. Chronic anticonvulsant carbamazepine therapy was shown to increase fentanyl clearance and decrease plasma concentrations in neurosurgical patients, which may attenuate the actions of fentanyl. A case report showed that treatment with slow-release oral morphine in a near-fatal fentanyl overdose patient was successful, despite the patient’s previous failures with methadone and buprenorphine/naloxone-based opioid agonist therapies, which could be considered potential alternative treatments.

Previous studies have reported the vaccine consisting of fentanyl hapten conjugated to tetanus toxoid or keyhole limpet hemocyanin carrier protein, and immunization with these vaccines reduced fentanyl biodistribution to the brain, and blunted its antinociceptive effects and respiratory depression in rodents,. Moreover, the conjugate vaccine stimulated the endogenous generation of antibodies with high affinity for a variety of fentanyl analogs, and was shown to blunt fentanyl reinforcement. A recent study screened and purified monoclonal antibodies (mAbs) from vaccinated mice, and found that the 6A4 mAb prevented the acute lethality of fentanyl, and reversed both fentanyl and carfentanil-induced antinociception as effective as naloxone. These findings suggest that immunopharmacotherapies including active vaccine or its combination with passive mAb may be potential and promising treatment strategies to address the current opioid crisis. Accumulating evidence also implicate the dysbiosis of gut microbiome in the pathophysiology of drug addiction, however data regarding fentanyl use is rare. Manipulating the compositions of the gut microbiome or its products may guide new adjuvant therapies for opioid addiction in the future.

A United States FDA Risk Evaluation and Mitigation Strategy (REMS) program was also implemented to assess transmucosal immediate-release fentanyls (TIRFs) and found that substantial rates of TIRFs were prescribed inappropriately,. With the findings of deficiencies in the structure and administration of TIRFs, the development of other REMSs is needed to ensure the safe and appropriate use of approved drugs, especially dangerous opioid drugs.

In conclusion, the crisis of opioid-related overdoses, especially fentanyl and its analogs, is a major threat to both individual and public health. Respiratory depression, cardiovascular effects, and neuropsychiatric symptoms are associated with fentanyl overdose and lethality. Naloxone is the standard rescue drug for fentanyl overdose, but its efficacy is inconsistent. Further clinical research is needed to optimize individualized medication-assisted treatments in patients who overdose on fentanyl and its analogs. To address the social, economic, and health problems that are associated with fentanyl and its analogs, coordinated efforts are needed to implement large-scale harm reduction strategies (e.g., naloxone distribution, innovative studies, and the development of novel drugs).

References 147

  1. 1.

    Poklis A. Fentanyl: a review for clinical and analytical toxicologists. J. Toxicol. Clin. Toxicol. 1995;33:439-447.

    Not in our library10.3109/15563659509013752

  2. 2.

    Clotz, M. A. & Nahata, M. C. Clinical uses of fentanyl, sufentanil, and alfentanil. Clin. Pharm.10, 581–593 (1991).

    Not in our library

  3. 3.

    Aldington D, Jagdish S. The fentanyl ‘lozenge’ story: from books to battlefield. J. R. Army Med. Corps. 2014;160:102-104.

    Not in our library10.1136/jramc-2013-000227

  4. 4.

    Stanley TH. The fentanyl story. J. Pain. 2014;15:1215-1226.

    Not in our library10.1016/j.jpain.2014.08.010

  5. 5.

    Schug SA, Ting S. Fentanyl formulations in the management of pain: an update. Drugs. 2017;77:747-763.

    Not in our library10.1007/s40265-017-0727-z

  6. 6.

    Henderson Gary L. Fentanyl-Related Deaths: Demographics, Circumstances, and Toxicology of 112 Cases. Journal of Forensic Sciences. 1991;36(2):13045J.

    Not in our library10.1520/jfs13045j

  7. 7.

    Hibbs J, Perper J, Winek CL. An outbreak of designer drug-related deaths in Pennsylvania. JAMA. 1991;265:1011-1013.

    Not in our library10.1001/jama.1991.03460080081037

  8. 8.

    Jalal Hawre, Buchanich Jeanine M., Roberts Mark S., Balmert Lauren C., Zhang Kun, Burke Donald S. Changing dynamics of the drug overdose epidemic in the United States from 1979 through 2016. Science. 2018;361(6408):eaau1184.

    Not in our library10.1126/science.aau1184

  9. 9.

    Suzuki J, El-Haddad S. A review: fentanyl and non-pharmaceutical fentanyls. Drug Alcohol Depend. 2017;171:107-116.

    Not in our library10.1016/j.drugalcdep.2016.11.033

  10. 10.

    Colon-Berezin C, Nolan ML, Blachman-Forshay J, Paone D. Overdose deaths involving fentanyl and fentanyl analogs—New York City, 2000–2017. Morb. Mortal. Wkly Rep. 2019;68:37-40.

    Not in our library10.15585/mmwr.mm6802a3

  11. 11.

    Nolan ML, Shamasunder S, Colon-Berezin C, Kunins HV, Paone D. Increased presence of fentanyl in cocaine-involved fatal overdoses: implications for prevention. J. Urban Health. 2019;96:49-54.

    Not in our library10.1007/s11524-018-00343-z

  12. 12.

    LaRue L, et al. Rate of fentanyl positivity among urine drug test results positive for cocaine or methamphetamine. JAMA Netw. Open. 2019;2:e192851.

    Not in our library10.1001/jamanetworkopen.2019.2851

  13. 13.

    Hedegaard, H., Warner, M. & Minino, A. M. Drug overdose deaths in the United States, 1999–2016. NCHS Data Brief294, 1–8 (2017).

    Not in our library

  14. 14.

    Pardo B, Reuter P. Facing fentanyl: should the USA consider trialling prescription heroin? Lancet Psychiatry. 2018;5:613-615.

    Not in our library10.1016/s2215-0366(18)30103-2

  15. 15.

    Lyden J, Binswanger IA. The United States opioid epidemic. Semin. Perinatol. 2019;43:123-131.

    Not in our library10.1053/j.semperi.2019.01.001

  16. 16.

    Jones CM, Einstein EB, Compton WM. Changes in synthetic opioid involvement in drug overdose deaths in the United States, 2010–2016. JAMA. 2018;319:1819-1821.

    Not in our library10.1001/jama.2018.2844

  17. 17.
    Drug and Opioid-Involved Overdose Deaths — United States, 2013–2017 · 2018
    No notice
  18. 18.

    Ahn JS, et al. Transdermal buprenorphine and fentanyl patches in cancer pain: a network systematic review. J. Pain Res. 2017;10:1963-1972.

    Not in our library10.2147/jpr.s140320

  19. 19.

    Mystakidou K, Katsouda E, Parpa E, Vlahos L, Tsiatas ML. Oral transmucosal fentanyl citrate: overview of pharmacological and clinical characteristics. Drug Deliv. 2006;13:269-276.

    Not in our library10.1080/10717540500394661

  20. 20.

    Katz P, Takyar S, Palmer P, Liedgens H. Sublingual, transdermal and intravenous patient-controlled analgesia for acute post-operative pain: systematic literature review and mixed treatment comparison. Curr. Med. Res. Opin. 2017;33:899-910.

    Not in our library10.1080/03007995.2017.1294559

  21. 21.

    Frank RG, Pollack HA. Addressing the fentanyl threat to public health. N. Engl. J. Med. 2017;376:605-607.

    Not in our library10.1056/nejmp1615145

  22. 22.

    Smialek, J. E., Levine, B., Chin, L., Wu, S. C. & Jenkins, A. J. A fentanyl epidemic in Maryland 1992. J. Forensic Sci.39, 159–164 (1994).

    Not in our library

  23. 23.

    Algren DA, et al. Fentanyl-associated fatalities among illicit drug users in Wayne County, Michigan (July 2005–May 2006). J. Med. Toxicol. 2013;9:106-115.

    Not in our library10.1007/s13181-012-0285-4

  24. 24.

    Ostling PS, et al. America’s opioid epidemic: a comprehensive review and look into the rising crisis. Curr. Pain Headache Rep. 2018;22:32.

    Not in our library10.1007/s11916-018-0685-5

  25. 25.

    Fischer B, Vojtila L, Rehm J. The ‘fentanyl epidemic’ in Canada—some cautionary observations focusing on opioid-related mortality. Prev. Med. 2018;107:109-113.

    Not in our library10.1016/j.ypmed.2017.11.001

  26. 26.

    Phalen P, Ray B, Watson DP, Huynh P, Greene MS. Fentanyl related overdose in Indianapolis: estimating trends using multilevel Bayesian models. Addict. Behav. 2018;86:4-10.

    Not in our library10.1016/j.addbeh.2018.03.010

  27. 27.

    Jones AA, et al. Rapid change in fentanyl prevalence in a community-based, high-risk sample. JAMA Psychiatry. 2018;75:298-300.

    Not in our library10.1001/jamapsychiatry.2017.4432

  28. 28.

    Roxburgh A, et al. Trends in heroin and pharmaceutical opioid overdose deaths in Australia. Drug Alcohol Depend. 2017;179:291-298.

    Not in our library10.1016/j.drugalcdep.2017.07.018

  29. 29.

    McKeown HE, Rook TJ, Pearson JR, Jones OAH. Is Australia ready for fentanyl? Sci. Justice. 2018;58:366-371.

    Not in our library10.1016/j.scijus.2018.04.004

  30. 30.
    Deaths Involving Fentanyl, Fentanyl Analogs, and U-47700 — 10 States, July–December 2016 · 2017
    No notice
  31. 31.

    Gomes T, et al. Contributions of prescribed and non-prescribed opioids to opioid related deaths: population based cohort study in Ontario, Canada. BMJ. 2018;362:k3207.

    Not in our library10.1136/bmj.k3207

  32. 32.

    Daniulaityte R, et al. Trends in fentanyl and fentanyl analogue-related overdose deaths - Montgomery County, Ohio, 2015–2017. Drug Alcohol Depend. 2019;198:116-120.

    Not in our library10.1016/j.drugalcdep.2019.01.045

  33. 33.

    Bijral, P., Hayhurst, K. P., Bird, S. M. & Millar, T. Prevalence of recent fentanyl use among treated users of illicit opioids in England: based on piloted urine drug screens. Clin. Toxicol.57, 368–371 (2019).

    Not in our library10.1080/15563650.2018.1527927

  34. 34.

    Hikin L, Smith PR, Ringland E, Hudson S, Morley SR. Multiple fatalities in the North of England associated with synthetic fentanyl analogue exposure: detection and quantitation a case series from early 2017. Forensic Sci. Int. 2018;282:179-183.

    Not in our library10.1016/j.forsciint.2017.11.036

  35. 35.

    Blachman-Forshay J, Nolan ML, McAteer JM, Paone D. Estimating the risk of exposure to fentanyl in New York city: testing drug residue in used syringes. Am. J. Public Health. 2018;108:1666-1668.

    Not in our library10.2105/ajph.2018.304694

  36. 36.

    Hayashi K, et al. Substance use patterns associated with recent exposure to fentanyl among people who inject drugs in Vancouver, Canada: a cross-sectional urine toxicology screening study. Drug Alcohol Depend. 2018;183:1-6.

    Not in our library10.1016/j.drugalcdep.2017.10.020

  37. 37.

    Park JN, Weir BW, Allen ST, Chaulk P, Sherman SG. Fentanyl-contaminated drugs and non-fatal overdose among people who inject drugs in Baltimore. Md. Harm Reduct. J. 2018;15:34.

    Not in our library10.1186/s12954-018-0240-z

  38. 38.

    Uuskula A, et al. Non-fatal overdoses and related risk factors among people who inject drugs in St. Petersburg, Russia and Kohtla-Jarve, Estonia. BMC Public Health. 2015;15:1255.

    Not in our library10.1186/s12889-015-2604-6

  39. 39.

    Geddes, L., Iversen, J., Memedovic, S. & Maher, L. Intravenous fentanyl use among people who inject drugs in Australia. Drug Alcohol Rev.37(Suppl. 1), S314–S322 (2018).

    Not in our library10.1111/dar.12668

  40. 40.

    Latimer J, Ling S, Flaherty I, Jauncey M, Salmon AM. Risk of fentanyl overdose among clients of the Sydney Medically Supervised Injecting Centre. Int J. Drug Policy. 2016;37:111-114.

    Not in our library10.1016/j.drugpo.2016.08.004

  41. 41.

    Dowell D, Noonan RK, Houry D. Underlying factors in drug overdose deaths. JAMA. 2017;318:2295-2296.

    Not in our library10.1001/jama.2017.15971

  42. 42.

    Giorgetti, A., Centola, C. & Giorgetti, R. Fentanyl novel derivative-related deaths. Hum. Psychopharmacol. 32, e2605 (2017).

    Not in our library10.1002/hup.2605

  43. 43.

    Amlani A, et al. Why the FUSS (Fentanyl Urine Screen Study)? A cross-sectional survey to characterize an emerging threat to people who use drugs in British Columbia, Canada. Harm Reduct. J. 2015;12:54.

    Not in our library10.1186/s12954-015-0088-4

  44. 44.

    Arfken CL, Suchanek J, Greenwald MK. Characterizing fentanyl use in methadone-maintained clients. J. Subst. Abus. Treat. 2017;75:17-21.

    Not in our library10.1016/j.jsat.2017.01.004

  45. 45.

    Cicero TJ, Ellis MS, Kasper ZA. Increases in self-reported fentanyl use among a population entering drug treatment: the need for systematic surveillance of illicitly manufactured opioids. Drug Alcohol Depend. 2017;177:101-103.

    Not in our library10.1016/j.drugalcdep.2017.04.004

  46. 46.

    Strike, C. & Watson, T. M. Losing the uphill battle? Emergent harm reduction interventions and barriers during the opioid overdose crisis in Canada. Int. J. Drug Policy.10.1016/j.drugpo.2019.02.005 (2019).

    Not in our library10.1016/j.drugpo.2019.02.005

  47. 47.

    Krieger MS, et al. High willingness to use rapid fentanyl test strips among young adults who use drugs. Harm Reduct. J. 2018;15:7.

    Not in our library10.1186/s12954-018-0213-2

  48. 48.

    Kennedy MC, et al. Willingness to use drug checking within future supervised injection services among people who inject drugs in a mid-sized Canadian city. Drug Alcohol Depend. 2018;185:248-252.

    Not in our library10.1016/j.drugalcdep.2017.12.026

  49. 49.

    Bergh MS, Bogen IL, Wilson SR, Oiestad AML. Addressing the fentanyl analogue epidemic by multiplex UHPLC–MS/MS analysis of whole blood. Ther. Drug Monit. 2018;40:738-748.

    Not in our library10.1097/ftd.0000000000000564

  50. 50.

    Palamar JJ, et al. Testing hair for fentanyl exposure: a method to inform harm reduction behavior among individuals who use heroin. Am. J. Drug Alcohol Abus. 2019;45:90-96.

    Not in our library10.1080/00952990.2018.1550652

  51. 51.

    Fogarty MF, Papsun DM, Logan BK. Analysis of fentanyl and 18 novel fentanyl analogs and metabolites by LC–MS–MS, and report of fatalities associated with methoxyacetylfentanyl and cyclopropylfentanyl. J. Anal. Toxicol. 2018;42:592-604.

    Not in our library10.1093/jat/bky035

  52. 52.

    Griswold MK, et al. A novel oral fluid assay (LC-QTOF-MS) for the detection of fentanyl and clandestine opioids in oral fluid after reported heroin overdose. J. Med. Toxicol. 2017;13:287-292.

    Not in our library10.1007/s13181-017-0632-6

  53. 53.

    Angelini DJ, et al. Evaluation of a lateral flow immunoassay for the detection of the synthetic opioid fentanyl. Forensic Sci. Int. 2019;300:75-81.

    Not in our library10.1016/j.forsciint.2019.04.019

  54. 54.

    Frisoni Paolo, Bacchio Erica, Bilel Sabrine, Talarico Anna, Gaudio Rosa, Barbieri Mario, Neri Margherita, Marti Matteo. Novel Synthetic Opioids: The Pathologist’s Point of View. Brain Sciences. 2018;8(9):170.

    Not in our library10.3390/brainsci8090170

  55. 55.

    Gaskey NJ, Ferriero L, Pournaras L, Seecof J. Use of fentanyl markedly increases nausea and vomiting in gynecological short stay patients. AANA J. 1986;54:309-311.

    Not in our library

  56. 56.

    Yang Q, et al. Efficacy and adverse effects of transdermal fentanyl and sustained-release oral morphine in treating moderate-severe cancer pain in Chinese population: a systematic review and meta-analysis. J. Exp. Clin. Cancer Res. 2010;29:67.

    Not in our library10.1186/1756-9966-29-67

  57. 57.

    Wei G, Moss J, Yuan CS. Opioid-induced immunosuppression: is it centrally mediated or peripherally mediated? Biochem. Pharm. 2003;65:1761-1766.

    Not in our library10.1016/s0006-2952(03)00085-6

  58. 58.

    Sacerdote P. Opioid-induced immunosuppression. Curr. Opin. Support. Palliat. Care. 2008;2:14-18.

    Not in our library10.1097/spc.0b013e3282f5272e

  59. 59.

    Pergolizzi J, et al. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone). Pain. Pr. 2008;8:287-313.

    Not in our library10.1111/j.1533-2500.2008.00204.x

  60. 60.

    Wolff RF, et al. Systematic review of adverse events of buprenorphine patch versus fentanyl patch in patients with chronic moderate-to-severe pain. Pain Manag. 2012;2:351-362.

    Not in our library10.2217/pmt.12.22

  61. 61.

    Gil-Gouveia R, Wilkinson PA, Kaube H. Severe hemiplegic migraine attack precipitated by fentanyl sedation for esophagogastroscopy. Neurology. 2004;63:2446-2447.

    Not in our library10.1212/01.wnl.0000147326.21231.74

  62. 62.

    Hass B, et al. Cost-effectiveness of strong opioids focussing on the long-term effects of opioid-related fractures: a model approach. Eur. J. Health Econ. 2009;10:309-321.

    Not in our library10.1007/s10198-008-0134-1

  63. 63.

    Bruera E, Pereira J. Acute neuropsychiatric findings in a patient receiving fentanyl for cancer pain. Pain. 1997;69:199-201.

    Not in our library10.1016/s0304-3959(96)03238-1

  64. 64.

    Comer SD, Cahill CM. Fentanyl: receptor pharmacology, abuse potential, and implications for treatment. Neurosci. Biobehav. Rev. 2019;106:49-57.

    Not in our library10.1016/j.neubiorev.2018.12.005

  65. 65.

    Volkow ND, Jones EB, Einstein EB, Wargo EM. Prevention and treatment of opioid misuse and addiction: a review. JAMA Psychiatry. 2019;76:208-216.

    Not in our library10.1001/jamapsychiatry.2018.3126

  66. 66.

    Schifano F, Chiappini S, Corkery JM, Guirguis A. Assessing the 2004–2018 fentanyl misusing issues reported to an international range of adverse reporting systems. Front. Pharm. 2019;10:46.

    Not in our library10.3389/fphar.2019.00046

  67. 67.

    Nadpara PA, et al. Risk factors for serious prescription opioid-induced respiratory depression or overdose: comparison of commercially insured and veterans health affairs populations. Pain Med. 2018;19:79-96.

    Not in our library10.1093/pm/pnx038

  68. 68.

    Baumann MH, Kopajtic TA, Madras BK. Pharmacological research as a key component in mitigating the opioid overdose crisis. Trends Pharm. Sci. 2018;39:995-998.

    Not in our library10.1016/j.tips.2018.09.006

  69. 69.

    Chen JC, Smith ER, Cahill M, Cohen R, Fishman JB. The opioid receptor binding of dezocine, morphine, fentanyl, butorphanol and nalbuphine. Life Sci. 1993;52:389-396.

    Not in our library10.1016/0024-3205(93)90152-s

  70. 70.

    Andersen HB, Christensen B, Findlay JW, Jansen JA. Pharmacokinetics of intravenous, intrathecal and epidural morphine and fentanyl in the goat. Acta Anaesthesiol. Scand. 1986;30:393-399.

    Not in our library10.1111/j.1399-6576.1986.tb02437.x

  71. 71.

    Jang Y, Yoburn BC. Evaluation of receptor mechanism mediating fentanyl analgesia and toxicity. Eur. J. Pharm. 1991;197:135-141.

    Not in our library10.1016/0014-2999(91)90512-o

  72. 72.

    Tschirhart JN, Li W, Guo J, Zhang S. Blockade of the human ether a-go-go-related gene (hERG) potassium channel by fentanyl. Mol. Pharm. 2019;95:386-397.

    Not in our library10.1124/mol.118.114751

  73. 73.

    Kiyatkin EA. Respiratory depression and brain hypoxia induced by opioid drugs: morphine, oxycodone, heroin, and fentanyl. Neuropharmacology. 2019;151:219-226.

    Not in our library10.1016/j.neuropharm.2019.02.008

  74. 74.

    Dahan A, et al. Comparison of the respiratory effects of intravenous buprenorphine and fentanyl in humans and rats. Br. J. Anaesth. 2005;94:825-834.

    Not in our library10.1093/bja/aei145

  75. 75.

    Solis E, Cameron-Burr KT, Shaham Y, Kiyatkin EA. Fentanyl-induced brain hypoxia triggers brain hyperglycemia and biphasic changes in brain temperature. Neuropsychopharmacology. 2018;43:810-819.

    Not in our library10.1038/npp.2017.181

  76. 76.

    Barash JA, et al. Acute amnestic syndrome associated with fentanyl overdose. N. Engl. J. Med. 2018;378:1157-1158.

    Not in our library10.1056/nejmc1716355

  77. 77.

    Kofke WA, Garman RH, Stiller RL, Rose ME, Garman R. Opioid neurotoxicity: fentanyl dose-response effects in rats. Anesth. Analg. 1996;83:1298-1306.

    Not in our library10.1213/00000539-199612000-00029

  78. 78.

    Duru UB, et al. An unusual amnestic syndrome associated with combined fentanyl and cocaine use. Ann. Intern. Med. 2018;169:662-663.

    Not in our library10.7326/l18-0411

  79. 79.

    Taylor RG, Budhram A, Lee DH, Mirsattari SM. Opioid-associated amnestic syndrome observed with fentanyl patch use. CMAJ. 2019;191:E337-E339.

    Not in our library10.1503/cmaj.181291

  80. 80.

    Solis, E., Jr., Cameron-Burr, K. T. & Kiyatkin, E. A. Heroin contaminated with fentanyl dramatically enhances brain hypoxia and induces brain hypothermia. eNeuro4, ENEURO.0323–17.2017 (2017).

    Not in our library10.1523/eneuro.0323-17.2017

  81. 81.

    Harper MH, Hickey RF, Cromwell TH, Linwood S. The magnitude and duration of respiratory depression produced by fentanyl and fentanyl plus droperidol in man. J. Pharm. Exp. Ther. 1976;199:464-468.

    Not in our library

  82. 82.

    Magosso E, Ursino M, van Oostrom JH. Opioid-induced respiratory depression: a mathematical model for fentanyl. IEEE Trans. Biomed. Eng. 2004;51:1115-1128.

    Not in our library10.1109/tbme.2004.827344

  83. 83.

    Goetz AM, et al. Adult respiratory distress syndrome associated with epidural fentanyl infusion. Crit. Care Med. 1994;22:1579-1583.

    Not in our library10.1097/00003246-199410000-00012

  84. 84.

    Chen SW, Maguire PA, Davies MF, Beatty MF, Loew GH. Evidence for mu1-opioid receptor involvement in fentanyl-mediated respiratory depression. Eur. J. Pharm. 1996;312:241-244.

    Not in our library10.1016/0014-2999(96)00571-7

  85. 85.

    Ren J, Ding X, Greer JJ. Activating alpha4beta2 nicotinic acetylcholine receptors alleviates fentanyl-induced respiratory depression in rats. Anesthesiology. 2019;130:1017-1031.

    Not in our library10.1097/aln.0000000000002676

  86. 86.

    Roozekrans M, et al. Two studies on reversal of opioid-induced respiratory depression by BK-channel blocker GAL021 in human volunteers. Anesthesiology. 2014;121:459-468.

    Not in our library10.1097/aln.0000000000000367

  87. 87.

    Dahan A, et al. Averting opioid-induced respiratory depression without affecting analgesia. Anesthesiology. 2018;128:1027-1037.

    Not in our library10.1097/aln.0000000000002184

  88. 88.

    Golder FJ, et al. Identification and characterization of GAL-021 as a novel breathing control modulator. Anesthesiology. 2015;123:1093-1104.

    Not in our library10.1097/aln.0000000000000844

  89. 89.

    Oden, R. V. & Karagianes, T. G. Postoperative myocardial ischemia possibly masked by epidural fentanyl analgesia. Anesthesiology74, 941–943 (1991).

    Not in our library10.1097/00000542-199105000-00023

  90. 90.

    Blair JR, Pruett JK, Crumrine RS, Balser JJ. Prolongation of QT interval in association with the administration of large doses of opiates. Anesthesiology. 1987;67:442-443.

    Not in our library10.1097/00000542-198709000-00033

  91. 91.

    Hilgenberg JC, Johantgen WC. Bradycardia after intravenous fentanyl during subarachnoid anesthesia. Anesth. Analg. 1980;59:162-163.

    Not in our library10.1213/00000539-198002000-00018

  92. 92.

    Zuin M, Rigatelli G, Roncon L. Use of fentanyl during percutaneous coronary interventions: safety and drawbacks. Cardiovasc. Drugs Ther. 2018;32:625-632.

    Not in our library10.1007/s10557-018-6835-5

  93. 93.

    McEvoy JW, et al. Effect of intravenous fentanyl on ticagrelor absorption and platelet inhibition among patients undergoing percutaneous coronary intervention: the PACIFY randomized clinical trial (platelet aggregation with ticagrelor inhibition and fentanyl). Circulation. 2018;137:307-309.

    Not in our library10.1161/circulationaha.117.031678

  94. 94.

    Ibrahim K, et al. Effect of intravenous fentanyl on ticagrelor absorption and platelet inhibition among patients undergoing percutaneous coronary intervention: design, rationale, and sample characteristics of the PACIFY randomized trial. Contemp. Clin. Trials. 2018;64:8-12.

    Not in our library10.1016/j.cct.2017.11.011

  95. 95.

    Takase I, Koizumi T, Fujimoto I, Yanai A, Fujimiya T. An autopsy case of acetyl fentanyl intoxication caused by insufflation of ‘designer drugs’. Leg. Med. 2016;21:38-44.

    Not in our library10.1016/j.legalmed.2016.05.006

  96. 96.

    Poklis J, et al. Two fatal intoxications involving butyryl fentanyl. J. Anal. Toxicol. 2016;40:703-708.

    Not in our library10.1093/jat/bkw048

  97. 97.

    Tsuchida H, Schubert A, Estafanous FG, Brum JM, Murray PA. Sigma receptor activation does not mediate fentanyl-induced attenuation of muscarinic coronary contraction. Anesth. Analg. 1996;82:982-987.

    Not in our library10.1097/00000539-199605000-00016

  98. 98.

    Mitra S. Opioid-induced hyperalgesia: pathophysiology and clinical implications. J. Opioid Manag. 2008;4:123-130.

    Not in our library10.5055/jom.2008.0017

  99. 99.

    Mao J. Opioid-induced abnormal pain sensitivity: implications in clinical opioid therapy. Pain. 2002;100:213-217.

    Not in our library10.1016/s0304-3959(02)00422-0

  100. 100.
    CaMKIIα may modulate fentanyl-induced hyperalgesia via a CeLC-PAG-RVM-spinal cord descending facilitative pain pathway in rats. · 2017
    Not checked
  101. 101.

    Li Z, et al. Activation of the extracellular signal-regulated kinase in the amygdale modulates fentanyl-induced hypersensitivity in rats. J. Pain. 2017;18:188-199.

    Not in our library10.1016/j.jpain.2016.10.013

  102. 102.

    Bart G. Maintenance medication for opiate addiction: the foundation of recovery. J. Addict. Dis. 2012;31:207-225.

    Not in our library10.1080/10550887.2012.694598

  103. 103.

    Doughty B, Morgenson D, Brooks T. Lofexidine: a newly FDA-approved, nonopioid treatment for opioid withdrawal. Ann. Pharmacother. 2019;53:746-753.

    Not in our library10.1177/1060028019828954

  104. 104.

    Gorodetzky CW, et al. A phase III, randomized, multi-center, double blind, placebo controlled study of safety and efficacy of lofexidine for relief of symptoms in individuals undergoing inpatient opioid withdrawal. Drug Alcohol Depend. 2017;176:79-88.

    Not in our library10.1016/j.drugalcdep.2017.02.020

  105. 105.

    Kinshella MW, Gauthier T, Lysyshyn M. Rigidity, dyskinesia and other atypical overdose presentations observed at a supervised injection site, Vancouver, Canada. Harm. Reduct. J. 2018;15:64.

    Not in our library10.1186/s12954-018-0271-5

  106. 106.

    Mayer S, et al. Characterizing fentanyl-related overdoses and implications for overdose response: findings from a rapid ethnographic study in Vancouver, Canada. Drug Alcohol Depend. 2018;193:69-74.

    Not in our library10.1016/j.drugalcdep.2018.09.006

  107. 107.

    Floyd CN, Warren JB. Opioids out of control. Br. J. Clin. Pharm. 2018;84:813-815.

    Not in our library10.1111/bcp.13346

  108. 108.

    Scheuermeyer FX, et al. Safety of a brief emergency department observation protocol for patients with presumed fentanyl overdose. Ann. Emerg. Med. 2018;72:1-8 e1.

    Not in our library10.1016/j.annemergmed.2018.01.054

  109. 109.

    Stone AC, Carroll JJ, Rich JD, Green TC. Methadone maintenance treatment among patients exposed to illicit fentanyl in Rhode Island: safety, dose, retention, and relapse at 6 months. Drug Alcohol Depend. 2018;192:94-97.

    Not in our library10.1016/j.drugalcdep.2018.07.019

  110. 110.

    Pendergrass SA, Crist RC, Jones LK, Hoch JR, Berrettini WH. The importance of buprenorphine research in the opioid crisis. Mol. Psychiatry. 2019;24:626-632.

    Not in our library10.1038/s41380-018-0329-5

  111. 111.

    Wakeman SE, et al. Impact of fentanyl use on buprenorphine treatment retention and opioid abstinence. J. Addict. Med. 2019;13:253-257.

    Not in our library10.1097/adm.0000000000000486

  112. 112.

    Walker EA, Young AM. Differential tolerance to antinociceptive effects of mu opioids during repeated treatment with etonitazene, morphine, or buprenorphine in rats. Psychopharmacology. 2001;154:131-142.

    Not in our library10.1007/s002130000620

  113. 113.

    Barrett AC, Smith ES, Picker MJ. Use of irreversible antagonists to determine the relative efficacy of mu-opioids in a pigeon drug discrimination procedure: comparison of beta-funaltrexamine and clocinnamox. J. Pharm. Exp. Ther. 2003;305:1061-1070.

    Not in our library10.1124/jpet.102.047068

  114. 114.

    Negus SS, Brandt MR, Gatch MB, Mello NK. Effects of heroin and its metabolites on schedule-controlled responding and thermal nociception in rhesus monkeys: sensitivity to antagonism by quadazocine, naltrindole and beta-funaltrexamine. Drug Alcohol Depend. 2003;70:17-27.

    Not in our library10.1016/s0376-8716(02)00331-9

  115. 115.

    Winger G, Woods JH. The effects of chronic morphine on behavior reinforced by several opioids or by cocaine in rhesus monkeys. Drug Alcohol Depend. 2001;62:181-189.

    Not in our library10.1016/s0376-8716(00)00166-6

  116. 116.

    Bisaga Adam. What should clinicians do as fentanyl replaces heroin? Addiction. 2019;114(5):782-783.

    Not in our library10.1111/add.14522

  117. 117.

    Kuczynska K, Grzonkowski P, Kacprzak L, Zawilska JB. Abuse of fentanyl: an emerging problem to face. Forensic Sci. Int. 2018;289:207-214.

    Not in our library10.1016/j.forsciint.2018.05.042

  118. 118.

    Fairbairn N, Coffin PO, Walley AY. Naloxone for heroin, prescription opioid, and illicitly made fentanyl overdoses: challenges and innovations responding to a dynamic epidemic. Int. J. Drug Policy. 2017;46:172-179.

    Not in our library10.1016/j.drugpo.2017.06.005

  119. 119.

    Rzasa Lynn R, Galinkin JL. Naloxone dosage for opioid reversal: current evidence and clinical implications. Ther. Adv. Drug Saf. 2018;9:63-88.

    Not in our library10.1177/2042098617744161

  120. 120.

    Lee JD, et al. Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): a multicentre, open-label, randomised controlled trial. Lancet. 2018;391:309-318.

    Not in our library10.1016/s0140-6736(17)32812-x

  121. 121.

    Tanum L, et al. Effectiveness of injectable extended-release naltrexone vs daily buprenorphine-naloxone for opioid dependence: a randomized clinical noninferiority trial. JAMA Psychiatry. 2017;74:1197-1205.

    Not in our library10.1001/jamapsychiatry.2017.3206

  122. 122.

    Bell A, Bennett AS, Jones TS, Doe-Simkins M, Williams LD. Amount of naloxone used to reverse opioid overdoses outside of medical practice in a city with increasing illicitly manufactured fentanyl in illicit drug supply. Subst. Abus. 2019;40:52-55.

    Not in our library10.1080/08897077.2018.1449053

  123. 123.

    Schumann H, Erickson T, Thompson TM, Zautcke JL, Denton JS. Fentanyl epidemic in Chicago, Illinois and surrounding Cook County. Clin. Toxicol. 2008;46:501-506.

    Not in our library10.1080/15563650701877374

  124. 124.

    Freise KJ, Newbound GC, Tudan C, Clark TP. Naloxone reversal of an overdose of a novel, long-acting transdermal fentanyl solution in laboratory Beagles. J. Vet. Pharm. Ther. 2012;35(Suppl. 2):45-51.

    Not in our library10.1111/j.1365-2885.2012.01409.x

  125. 125.

    Greene JA, Deveau BJ, Dol JS, Butler MB. Incidence of mortality due to rebound toxicity after ‘treat and release’ practices in prehospital opioid overdose care: a systematic review. Emerg. Med. J. 2019;36:219-224.

    Not in our library10.1136/emermed-2018-207534

  126. 126.

    Karamouzian, M., Kuo, M., Crabtree, A. & Buxton, J. A. Correlates of seeking emergency medical help in the event of an overdose in British Columbia, Canada: findings from the Take Home Naloxone program. Int. J. Drug Policy.10.1016/j.drugpo.2019.01.006 (2019).

    Not in our library10.1016/j.drugpo.2019.01.006

  127. 127.

    Latkin CA, Dayton L, Davey-Rothwell MA, Tobin KE. Fentanyl and drug overdose: perceptions of fentanyl risk, overdose risk behaviors, and opportunities for intervention among people who use opioids in Baltimore, USA. Subst. Use Misuse. 2019;54:998-1006.

    Not in our library10.1080/10826084.2018.1555597

  128. 128.

    Irvine MA, et al. Distribution of take-home opioid antagonist kits during a synthetic opioid epidemic in British Columbia, Canada: a modelling study. Lancet Public Health. 2018;3:e218-e225.

    Not in our library10.1016/s2468-2667(18)30044-6

  129. 129.

    McDonald R, Campbell ND, Strang J. Twenty years of take-home naloxone for the prevention of overdose deaths from heroin and other opioids-conception and maturation. Drug Alcohol Depend. 2017;178:176-187.

    Not in our library10.1016/j.drugalcdep.2017.05.001

  130. 130.

    Elzey MJ, Fudin J, Edwards ES. Take-home naloxone treatment for opioid emergencies: a comparison of routes of administration and associated delivery systems. Expert Opin. Drug Deliv. 2017;14:1045-1058.

    Not in our library10.1080/17425247.2017.1230097

  131. 131.

    Kim HK, Connors NJ, Mazer-Amirshahi ME. The role of take-home naloxone in the epidemic of opioid overdose involving illicitly manufactured fentanyl and its analogs. Expert Opin. Drug Saf. 2019;18:465-475.

    Not in our library10.1080/14740338.2019.1613372

  132. 132.

    Yong Z, et al. Nalmefene reverses carfentanil-induced loss of righting reflex and respiratory depression in rats. Eur. J. Pharm. 2014;738:153-157.

    Not in our library10.1016/j.ejphar.2014.05.044

  133. 133.

    Palpacuer C, et al. Risks and benefits of nalmefene in the treatment of adult alcohol dependence: a systematic literature review and meta-analysis of published and unpublished double-blind randomized controlled trials. PLoS Med. 2015;12:e1001924.

    Not in our library10.1371/journal.pmed.1001924

  134. 134.

    Keating GM. Nalmefene: a review of its use in the treatment of alcohol dependence. CNS Drugs. 2013;27:761-772.

    Not in our library10.1007/s40263-013-0101-y

  135. 135.

    Castera P, et al. Nalmefene, given as needed, in the routine treatment of patients with alcohol dependence: an interventional, open-label study in primary care. Eur. Addict. Res. 2018;24:293-303.

    Not in our library10.1159/000494692

  136. 136.

    Fragale JE, Pantazis CB, James MH, Aston-Jones G. The role of orexin-1 receptor signaling in demand for the opioid fentanyl. Neuropsychopharmacology. 2019;44:1690-1697.

    Not in our library10.1038/s41386-019-0420-x

  137. 137.

    Obeng S, et al. Characterization of 17-cyclopropylmethyl-3,14beta-dihydroxy-4,5alpha-epoxy-6alpha-(indole-7-carboxami do)morphinan (NAN) as a novel opioid receptor modulator for opioid use disorder treatment. ACS Chem. Neurosci. 2019;10:2518-2532.

    Not in our library10.1021/acschemneuro.9b00038

  138. 138.

    Nozari A, et al. Prolonged therapy with the anticonvulsant carbamazepine leads to increased plasma clearance of fentanyl. J. Pharm. Pharm. 2019;71:982-987.

    Not in our library10.1111/jphp.13079

  139. 139.

    Prinsloo, G., Ahamad, K. & Socias Me, Md M. Successful treatment with slow-release oral morphine following afentanyl-related overdose: a case report. Subst. Abus.10.1080/08897077.2019.1576086 (2019).

    Not in our library10.1080/08897077.2019.1576086

  140. 140.

    Bremer PT, et al. Combatting synthetic designer opioids: a conjugate vaccine ablates lethal doses of fentanyl class drugs. Angew. Chem. Int. Ed. Engl. 2016;55:3772-3775.

    Not in our library10.1002/anie.201511654

  141. 141.

    Raleigh MD, et al. A fentanyl vaccine alters fentanyl distribution and protects against fentanyl-induced effects in mice and rats. J. Pharm. Exp. Ther. 2019;368:282-291.

    Not in our library10.1124/jpet.118.253674

  142. 142.

    Townsend EA, et al. Conjugate vaccine produces long-lasting attenuation of fentanyl vs. food choice and blocks expression of opioid withdrawal-induced increases in fentanyl choice in rats. Neuropsychopharmacology. 2019;44:1681-1689.

    Not in our library10.1038/s41386-019-0385-9

  143. 143.

    Smith LC, et al. Monoclonal antibodies for combating synthetic opioid intoxication. J. Am. Chem. Soc. 2019;141:10489-10503.

    Not in our library10.1021/jacs.9b04872

  144. 144.

    Meckel KR, Kiraly DD. A potential role for the gut microbiome in substance use disorders. Psychopharmacology. 2019;236:1513-1530.

    Not in our library10.1007/s00213-019-05232-0

  145. 145.

    Rollman JE, et al. Assessment of the FDA Risk Evaluation and Mitigation Strategy for transmucosal immediate-release fentanyl products. JAMA. 2019;321:676-685.

    Not in our library10.1001/jama.2019.0235

  146. 146.

    Fleischman W, Auth D, Shah ND, Agrawal S, Ross JS. Association of a Risk Evaluation and Mitigation Strategy program with transmucosal fentanyl prescribing. JAMA Netw. Open. 2019;2:e191340.

    Not in our library10.1001/jamanetworkopen.2019.1340

  147. 147.

    Sarpatwari A, Curfman G. Mitigating health risks of prescription drugs: lessons from FDA oversight of opioid products. JAMA. 2019;321:651-653.

    Not in our library10.1001/jama.2019.0236

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.